Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

@article{Goto2004MultiinstitutionalPI,
  title={Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer},
  author={K Yodokawa Goto and Ikuo Sekine and Yutaka Nishiwaki and Ryutaro Kakinuma and Kaoru Kubota and Takuya Matsumoto and Hironobu Ohmatsu and Seiji Niho and Tetsuro Kodama and Tetsu Shinkai and Tetsuhiko Tamura and Yuichiro Ohe and Hideo Kunitoh and Noboru Yamamoto and Hiroshi Nokihara and Kimihide Yoshida and Takahiko Sugiura and Kaoru Matsui and Nagahiro George Saijo},
  journal={British Journal of Cancer},
  year={2004},
  volume={91},
  pages={659 - 665}
}
Irinotecan (CPT-11) has been shown to exhibit excellent antitumour activity against small-cell lung cancer (SCLC). A multi-institutional phase II study was therefore conducted to evaluate the efficacy and toxicity of CPT-11 combined with cisplatin (CDDP) and etoposide (ETOP) (PEI regimen) for the treatment of sensitive relapsed SCLC. Patients who responded to first-line chemotherapy but relapsed more than 8 weeks after the completion of first-line therapy (n=40) were treated using the PEI… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Gemcitabine and paclitaxel as second line treatment in small cell lung cancer. A multicentric phase II study

  • M Domine, J Larriba, +9 authors F Diaz
  • Proc Am Soc Clin Oncol
  • 2001
Highly Influential
1 Excerpt

A phase II study of irinotecan in patients with small cell

  • T Le Chevalier, N Ibrahim, +4 authors J Pujol
  • 1997
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…